Tanios S. Bekaii-Saab, MD, on Next-Generation Sequencing for Gastrointestinal Cancer

Video

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Next-generation sequencing has revolutionized genomic research, helping oncologists to deliver the proper treatment to the proper target, thereby improving outcomes.

Specifically for patients with gastrointestinal cancers, precision therapy has represented a paradigm shift in the way oncologists approach patient care.

In an interview with CancerNetwork®, Tanios S. Bekaii-Saab, MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed why next-generation sequencing is so important for patients with gastrointestinal cancers, as well as the need to make genomic sequencing the standard of care for this entire patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Related Content